Investigation & Intelligence Feeds
Nearly 14,000 Voices Weigh In: What the CFPB Heard on the Open Banking Rule
The Consumer Financial Protection Bureau (CFPB) has once again found itself at the center of an intense policy debate....By: Goodwin
PTAB Grants Institution of Four PGRs related to Merck’s Keytruda Qlex™
Beginning in November 2024, Merck Sharp & Dohme, LLC (“Merck”) requested post-grant review (“PGR”) of 14 patents owned by Halozyme,...
Xbrane Enters into Conditional Financing Deal Related to Ranibizumab Biosimilar
As we have previously reported, on June 21, 2023, the FDA accepted Xbrane’s sBLA for LUCAMZI, a proposed ranibizumab biosimilar to Gene...
New York State attorney general discovers firm had two data breaches
On October 20, the New York State attorney general, in a press release, announced a settlement with a certified public accounting firm ...
Decoded – Technology Law Insights, V 6, Issue 10, 2025
California Breaks New Ground with First-Ever AI Companion Chatbot Safety Law - “SB 243 sets mandatory safety protocols to shield chil...
Higher Education and the Next Wave of Pixel-Tracking Litigation: Lessons from the Michigan VPPA Decision
A recent decision from the U.S. District Court for the Western District of Michigan, Goodman v. Hillsdale College (No. 1:25-cv-417, Oct...
Fourth Circuit: Leaked Data Breach Information Must Be Publicly Available to Cause ‘Concrete Injury’
On October 14, 2025, the Fourth Circuit issued its opinion in Holmes v. Elephant Insurance Company, clarifying that plaintiffs in data ...
PTAB Grants Amgen’s Request for Adverse Judgment Prior to Institution of Trial in Opdivo® IPR2025-00603
On October 1, 2025, the PTAB granted Amgen’s request for adverse judgment based on Bristol-Myers Squibb’s (“BMS”) statutory disclaimer ...
AI Legal Watch: October 2025
On September 29, 2025, California Governor Gavin Newsom signed into law Senate Bill 53 (“SB 53”), which includes the Transparency in Fr...
In re Entresto (sacubitril/valsartan) Patent Litigation (Novartis Pharms. Corp. v. MSN Pharms. Inc.)
Nature of the Case and Issue(s) Presented: Novartis holds the NDA for Entresto, a drug used to treat heart failure, having the active i...